SCENTMATIC
SCENTMATIC Inc (CEO: Toshiharu Kurisu, Head office: Tokyo, Japan), which proposes new customer experiences through the digitization of fragrance, announced that their AI service that verbalizes fragrance KAORIUM has been selected as “Retracing innovation and ideas that defined the lifestyle trends of 2023” by STIRworld.com, a leading global digital magazine in the fields of design, architecture, and arts.
* KAORIUM is a registered trademark of SCENTMATIC Inc.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328876250/en/
What's KAORIUM? Read scents, smell words; A journey of fragrance discovery that ignites the olfactory imagination. Finding a perfume is a challenge. Fragrances are hard to grasp, and expressing our preferences can be tough. KAORIUM by SCENTMATIC is an entirely novel approach to fragrance exploration that decodes the enigmatic world of scents and helps people discover new fragrances intuitively through language. Harnessing state-of-the-art technology, our mission is to deliver olfactory moments of delight. When a scent is placed on the coaster, the impression of the scent is visualized in words. By expressing sensory perceptions through language, scents that were once difficult to discern become more clearly perceivable. (Graphic: Business Wire)
STIRworld.com Article page (Published 17 December 2023)
“Retracing innovation and ideas that defined the lifestyle trends of 2023”
https://www.stirworld.com/see-features-retracing-innovation-and-ideas-that-defined-the-lifestyle-trends-of-2023
The article introduces KAORIUM as one of the lifestyle trends that will have a major impact on the global design structure in 2023. The article describes KAORIUM’s process of scent, language, and artificial intelligence uniting to refine the user's scent preferences as “an immersive experience”. KAORIUM was highly evaluated as a lifestyle trend for 2023, defining a new retail experience that cannot be found in traditional perfume selling counters.
About KAORIUM
https://www.youtube.com/embed/0fpDr3zgjeM?feature=oembed
The article was also featured on the Instagram account of STIRworld.com.
STIRworld.com Instagram reel video (Posted on 20 December 2023)
https://www.instagram.com/reel/C1CqKsNywAD/?igsh=cXJxczUzanhxa2to
KAORIUM was in the spotlight when we exhibited this AI system that mutually converts scents and words at the London Design Festival 2023, one of the world's leading design events, held in London, UK, for eight days from 16 to 24 September 2023.
STIRworld.com Article page (Published on 19 September 2023)
https://www.stirworld.com/see-lifestyle-scentmatics-kaorium-at-ldf-2023-explores-language-and-emotion-in-fragrance-selection
In the interview with STIR, Kurisu, Managing Director of SCENTMATIC, introduced the innovations brought by KAORIUM to the Japanese retail industry, as well as its future potential and social impact.
GET IN TOUCH
https://scentmatic.co.jp/contact-en
[SCENTMATIC, Inc.]
SCENTMATIC was established in 2019 as a co-creation fragrance business design group that can add "emotional experience value" to everything using an AI system that verbalizes fragrance. Focusing on the most unknown area of the five senses “smell”, we have developed KAORIUM, an AI tool that verbalizes fragrance. KAORIUM is expected to help businesses to utilize fragrance in a variety of ways. SCENTMATIC is working on the 'digitalization of the sense of smell'. It will revolutionize business in all industries by evolving people's senses through the 'experience of smell' using fragrance and words.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328876250/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom